Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-9722 · 2 trials · 2 indications
To determine the maximum tolerated dose of CEP-9722, as defined by dose-limiting toxicities (DLTs) reported during the second 21-day treatment cycle (the first cycle of CEP-9722 administration).
| Arm | Type | Description |
|---|---|---|
| CEP-9722 in combination with Gemcitabine and Cisplatin | EXPERIMENTAL | Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator. |
| 1 | EXPERIMENTAL | CEP-9722 alone and in combination therapy with temozolomide. |
| Name | Type | Description |
|---|---|---|
| CEP-9722 | DRUG | CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study. |
| Gemcitabine | DRUG | Gemcitabine will be administered at 1250 mg/m\^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient. |
| Cisplatin | DRUG | Cisplatin will be administered at 75 mg/m\^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient. |
Inclusion Criteria: * Written informed consent is obtained. The patient has a either a histologically or cytologically confirmed malignant advanced solid tumor or a mantle cell lymphoma (and has experienced failure of as least 1 previous therapy) and the patient may benefit from the combination of ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CEP-9722 is an investigational small molecule being studied for the treatment of advanced solid tumors and mantle cell lymphoma. It has been evaluated in Phase 1 clinical trials in patients with these conditions.
CEP-9722 is being developed by Teva Pharmaceutical Industries Limited, which is publicly traded under the ticker TEVA.
CEP-9722 is in Phase 1 clinical development. It has completed two Phase 1 trials, and it remains an investigational drug that is not yet approved for any use.
CEP-9722 has been studied in two completed Phase 1 trials. NCT00920595 evaluated CEP-9722 as a single agent and in combination with temozolomide in advanced solid tumors. NCT01345357 studied CEP-9722 in combination with gemcitabine and cisplatin in advanced solid tumors or mantle cell lymphoma.
No alternative names for CEP-9722 have been disclosed. It is identified solely by its code name CEP-9722 in clinical trial records.